Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04075903 · ClinicalTrials.gov registry record · NA
Gout in the ED and Improving Research Participation
A NA study of Gout, sponsored by University of Alabama at Birmingham.
- Active
- Registry status
- NA
- Development phase
- 200
- Enrollment target
- 4
- Study locations
NCT04075903: Active NA study of Gout, sponsored by University of Alabama at Birmingham.
NCT04075903 is a NA study of Gout that is active but no longer recruiting, run by University of Alabama at Birmingham. The registered enrollment target is 200 participants, below the 8,882-participant average among 34 other Gout trials with a reported enrollment target (98% lower). The trial reports 4 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04075903, a NA study of Gout, is active but no longer recruiting, sponsored by University of Alabama at Birmingham.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 200 participants
- Enrollment target
- 4
- Study locations
Study Summary
The prevalence of gout has been steadily increasing over several decades and is correlated with the rising burden of obesity, chronic cardiac and renal disease; all conditions overrepresented in the Southeastern U.S. - particularly in African Americans. Through a novel emergency department led intervention we aim to improve the care patients with gout receive, both during acute exacerbations and long-term. A secondary goal of the project is to concurrently enhance participation of minorities in biomedical research in the Deep South.
Primary Outcome
Proportion of participants who attend a primary care or specialist visits for gout treatment
Conditions Studied
Interventions
- BEHAVIORAL Storytelling
Study Locations (4)
Alabama
- University of Alabama at Birmingham - Birmingham
Iowa
- University of Iowa Hospitals and Clinics - Iowa City
Massachusetts
- Massachusetts General Hospital - Boston
Ohio
- MetroHealth Medical Center - Cleveland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 200 participants |
| Start Date | 2021-06-01 |
| Est. Completion | 2026-02-01 |
| Phase | NA |
What the registry record for NCT04075903 still lists
NCT04075903 is an interventional study that assigns participants to a tested intervention. The registered 200 participants enrollment target is mid-sized for trials with a published cap, below the 8,882-participant average among 34 other Gout trials with a reported enrollment target (98% lower).
The record links to 1 condition, with Gout appearing as the primary indexed condition, and to 1 intervention - of which Storytelling is the first listed.
NCT04075903 reports a single indexed study location in Alabama, Iowa, Massachusetts.
Frequently Asked Questions
What is clinical trial NCT04075903 about?
NCT04075903 is a clinical study titled "Gout in the ED and Improving Research Participation". The prevalence of gout has been steadily increasing over several decades and is correlated with the rising burden of obesity, chronic cardiac and renal disease; all conditions overrepresented in the Southeastern U.S. - particularly in African Americans. Through a novel emergency department led inter...
What is the current status of trial NCT04075903?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 200 participants. The study started on 2021-06-01. Estimated completion is 2026-02-01.
What conditions does trial NCT04075903 study?
This clinical trial studies the following conditions: Gout.
What interventions are being tested in trial NCT04075903?
The interventions under investigation include: Storytelling (BEHAVIORAL).
Who is sponsoring clinical trial NCT04075903?
This trial is sponsored by University of Alabama at Birmingham, which has 1,160 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04075903 being conducted?
This trial has 4 study locations across Alabama, Iowa, Massachusetts, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Gout
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04075903's enrollment target sits among peer trials
200 12th of 34 higher than 22 of 34 other Gout trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Gout trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Dose Response of Exercise for Arthritis Management
RECRUITING · NA
-
Improving Gout Care After an ED Visit
RECRUITING · NA
-
Novel Methods for Ascertainment of Gout Flares -A Pilot Study
COMPLETED · NA
-
The Diet Gout Trial
COMPLETED · NA
-
Pharmacokinetics and Pharmacodynamics of Anthocyanins
COMPLETED · NA
-
UR+AIMS Gout Wearable Skin Uric Acid Monitor Study
COMPLETED · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00107289 · 200 participants · Phase 2
Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma
- NCT00109174 · 200 participants · NA
MRS Measurement of Glutamate and GABA Metabolism in Brain
- NCT00177268 · 200 participants
Blood, Urine, and Tissue Collection for Cutaneous Lymphoma, Eczema, and Atopic Dermatitis Research
- NCT00493688 · 200 participants
A Study to Determine Whether Perioperative Energy Dynamics Correlates With Postoperative Outcomes
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI